Shares of the small biotech Inhibitex plunged this morning after the company reported that a late-stage trial of an infant anti-infection drug failed to hit its primary endpoint. In addition, researchers said that there were no favorable trends for secondary endpoints. "The outcome of the trial was unexpected against the background of our preclinical studies and favorable Phase II trends such that additional scrutiny is warranted," stated William D. Johnston, Ph.D., president and CEO of Inhibitex. Release